Page 1

AstraZeneca PLC 12 November 2021 07:00 GMT Year to date and Q3 2021 results AstraZeneca reinforces its scientific leadership through exceptional pipeline delivery and the addition of Alexion in the quarter Total Revenue in the year to date , including Alexion from 21 July 2021 , was $ 25,406m , representing growth of 32 % ( 28 % at CER ) . Total Revenue in the third quarter increased by 50 % ( 48 % at CER ) to $ 9,866m Excluding the pandemic COVID - 19 vaccine , Total Revenue increased 21 % ( 17 % at CER ) in the year to date to $ 23,187m , and by 34 % ( 32 % at CER ) in the quarter to $ 8,816m Eight positive Phase III results since June , with potential to change standard of care in several diseases Alexion integration progressing well , creating new opportunities in rare diseases Operating Expenses in the quarter reflected the addition of Alexion , as well increased R & D expenses across multiple programs , investment in our COVID - 19 medicines , and increased SG & A from pre - launch activities following successful pipeline delivery Earnings guidance for the full year is unchanged In the year to date , AstraZeneca delivered double - digit revenue growth from its Oncology , CVRM¹ and R & 1² medicines , and established its Rare Disease capability with the acquisition of Alexion Pharmaceuticals Inc. ( Alexion ) . Rare disease is a high - growth area with rapid innovation and significant unmet medical need . Since June , AstraZeneca has made significant progress with its late - stage pipeline , reporting eight positive Phase III trial results and the approval of Saphnelo ( anifrolumab ) in the US for the treatment of systemic lupus erythematosus , and Ultomiris in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria . Enhertu received a Breakthrough Therapy Designation from the US FDA³ following ground - breaking results from the DESTINY - Breast03 trial . The Company also announced positive results for Lynparza in prostate cancer , Imfinzi plus tremelimumab in liver cancer , Imfinzi in biliary tract cancer , PT027 in asthma , ALXN1840 in Wilson disease , and AZD7442 in COVID - 19 prophylaxis and treatment . Pascal Soriot , Chief Executive Officer , commented : " AstraZeneca's scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery , with eight positive late - stage readouts across seven medicines since June , including our long acting antibody combination showing promise in both prevention and treatment of COVID - 19 . The addition of Alexion furthers our commitment to bring transformative therapies to patients around the world , and I am proud of our colleagues ' ongoing dedication and focus . Our broad portfolio of medicines and diversified geographic exposure provides a robust platform for long - term sustainable growth . Following accelerated investment in upcoming launches after positive data flow , we expect a solid finish to the year and our earnings guidance is unchanged . " Table 1 : Revenue and EPS summary - Product Sales - Collaboration Revenue Total Revenue - Less pandemic COVID - 19 vaccine5 Total Revenue ex - pandemic vaccine Reported® EPS⁹ Core¹⁰ EPS Impact of pandemic vaccine on EPS YTD 2021 Actual % $ m Change 25,043 363 AstraZeneca What science can do 25,406 2,219 23,187 $ 0.33 $ 3.59 $ ( 0.03 ) 33 10 32 n / m6 21 ( 80 ) 22 n / m CER4 % change $ m 9,741 125 9,866 1,050 8,816 29 10 28 n / m 17 ( 65 ) $ ( 1.10 ) 23 $ 1.08 n / m $ 0.01 Q3 2021 Actual % CER % Change change 49 n / m 50 n / m 34 n / m 14 n / m 47 n / m 48 n / m 32 n / m 15 n / m 1